Medication info

Aizatan Plus Tablet

Prescription medicationTabletApproval withdrawn
Ingredient · strength
Irbesartan›150mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Dongwha Pharmaceutical Co., Ltd.
Appearance
Pink, double-convex, elongated film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 200803386 · Notified 2008.03.27

This product's status changed to Approval withdrawn on 2024.01.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension
Who uses it
Adults · Children
Adult dosage
This medicine is administered once daily, regardless of meals. Titration to the appropriate dose of each ingredient (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered concomitantly with other antihypertensive agents. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized in consideration of baseline blood pressure, target blood pressure, and the anticipated increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is generally initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is required in patients with renal impairment and creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is required for patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is required for older adults.
Children's dosage
○ Children The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Dongwha Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used for patients with essential hypertension. It is administered to those whose blood pressure is not adequately controlled by monotherapy, and in the initial treatment of patients with moderate to severe hypertension (stage 2) who require combination therapy to reach treatment goals. This effectively manages blood pressure and improves health.

Dosage and Administration

Adult dosage

This medicine is administered once daily, regardless of meals. Titration to the appropriate dose of each ingredient (irbesartan and hydrochlorothiazide) is recommended. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - For patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone, administer 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily. - For patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer 1 tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered concomitantly with other antihypertensive agents. 2. When this medicine is to be used as initial therapy in patients with moderate or severe hypertension (stage 2), treatment should be individualized in consideration of baseline blood pressure, target blood pressure, and the anticipated increase in the likelihood of achieving the treatment goal compared with monotherapy. Treatment is generally initiated with 1 tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended for patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred in this patient population. No dose adjustment is required in patients with renal impairment and creatinine clearance of 30 mL/min or greater. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is required for patients with mild ~ moderate hepatic impairment. ○ Older adults No dose adjustment is required for older adults.

Children's dosage

○ Children The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if administered to pregnant women, so it must be discontinued immediately if pregnancy is confirmed. Women who may become pregnant or are breastfeeding, individuals with allergies to specific medications, and patients with severe renal impairment should not use this drug. Special precautions are necessary for patients with hypotension, renal function problems, liver disease, or specific cardiac conditions when using this drug. While taking this medication, side effects such as dizziness, fatigue, nausea, vomiting, and abnormal urination may occur, and there may be an increased risk of skin cancer, so sun exposure should be avoided and skin condition should be monitored periodically. Caution should be taken while driving or operating machinery as dizziness or fatigue may occur, and if symptoms of excessively low blood pressure arise, immediate consultation with medical personnel is required. This medication can be used with other antihypertensive medications, but interactions may occur with lithium, certain diuretics, and potassium-related drugs, so it's important to inform healthcare providers about all medications being taken. It is safest to avoid use during pregnancy or breastfeeding, especially during breastfeeding, as it may affect the baby through breast milk. Safety and efficacy have not been established for children and adolescents, so it is not recommended for them. Elderly patients may be more sensitive to this medication, so caution is advised when using it. Patients should have their renal function and electrolyte status regularly checked through blood tests, and any abnormal symptoms should be reported to healthcare providers immediately. In case of overdose, symptoms such as hypotension, electrolyte imbalances, and dehydration may occur, so it is critical to adhere strictly to the prescribed dosage, and any issues should prompt immediate emergency treatment. This medication should be kept out of the reach of children and stored in its original container to prevent quality deterioration and misuse.

Side effects

Dizziness, fatigue, nausea, vomiting, abnormal urination, elevated BUN, increased creatine kinase, elevated creatinine, orthostatic dizziness, headache, syncope, hypotension, tachycardia, edema, flushing, cough, diarrhea, dyspepsia, dysgeusia, jaundice, hepatitis, abnormal liver function, sexual dysfunction, changes in libido, renal impairment, limb edema, arthralgia, myalgia, tinnitus, angioedema, rash, urticaria, hyperkalemia, decreased serum potassium, decreased serum sodium, herpes zoster, colon cancer, hematoma, thrombocytopenia, depression, sleep disorders, orthostatic hypotension, arrhythmia, aplastic anemia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia, respiratory distress, pancreatitis, anorexia, constipation, gastric irritation, sialadenitis, loss of appetite, interstitial nephritis, renal dysfunction, transient blurred vision, xanthopsia, weakness, muscle cramps, anaphylactoid reaction, toxic epidermal necrolysis, necrotizing vasculitis, cutaneous erythematous lupus-like reaction, cutaneous erythematous lupus reactivation, photosensitivity reaction, fever, electrolyte imbalance, hyperuricemia, diabetes, hyperglycemia, elevated cholesterol, increased triglycerides, hypokalemia, hyponatremia, hypochloremic metabolic alkalosis, muscle spasms, drowsiness, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. It is advisable to keep the storage temperature between 1 degree and 30 degrees Celsius room temperature. Proper storage will help maintain the drug's effectiveness.

Appearance and packaging

Appearance

Pink, double-convex, elongated film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.